Compare FSBC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | FTRE |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.4M | 829.3M |
| IPO Year | 2021 | 2023 |
| Metric | FSBC | FTRE |
|---|---|---|
| Price | $40.45 | $13.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $41.90 | $14.06 |
| AVG Volume (30 Days) | 81.6K | ★ 1.5M |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 28.32 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $30.25 | N/A |
| Revenue Next Year | $12.30 | $3.09 |
| P/E Ratio | $46.87 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $26.26 | $3.97 |
| 52 Week High | $42.26 | $18.67 |
| Indicator | FSBC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 59.26 |
| Support Level | $39.92 | $8.85 |
| Resistance Level | $41.58 | $18.26 |
| Average True Range (ATR) | 1.02 | 0.82 |
| MACD | -0.12 | 0.07 |
| Stochastic Oscillator | 28.51 | 54.77 |
Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.